Division Head
Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ)
Heidelberg, Baden-Wurttemberg, Germany
Stefan Fröhling is Head of the Division of Translational Medical Oncology at the German Cancer Research Center (DKFZ) and Managing Director of the National Center for Tumor Diseases (NCT) Heidelberg. His work at the interface of cancer research and clinical care centers on multidimensional tumor characterization as a basis for clinical trials investigating novel cancer therapies. In addition to his activities in cross-entity precision oncology, Stefan focuses on translating insights into the biology of rare cancers into novel diagnostic and therapeutic strategies. Locally, he directs the NCT Molecular Precision Oncology Program. On a national level, he coordinates the Research Platform “Cancer Genome Analysis” of the German Cancer Consortium (DKTK) and the DKFZ/NCT/DKTK MASTER (Molecularly Aided Stratification for Tumor Eradication Research) Program, activities that have paved the way for the widespread implementation of molecularly guided precision oncology in Germany. Internationally, he is a member of the Board of Directors of Cancer Core Europe and has long been active in the European Hematology Association, including a four-year term as an elected board member. Besides his scientific and clinical activities, which are characterized by a strong commitment to patient involvement, Stefan is interested in the education and training of physician-scientists and medical scientists.
Disclosure information not submitted.
Session 7: Novel Diagnostics and Bioinfomatics
Friday, November 3, 2023
11:30 AM – 12:30 PM
